D Lawrence Wickerham
Overview
Explore the profile of D Lawrence Wickerham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
9823
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al.
J Clin Oncol
. 2023 Jul;
41(20):3565-3575.
PMID: 37406456
Purpose: The 21-gene recurrence score (RS) assay quantifies the likelihood of distant recurrence in women with estrogen receptor-positive, lymph node-negative breast cancer treated with adjuvant tamoxifen. The relationship between the...
2.
Kim R, Song N, Gavin P, Salgado R, Bandos H, Kos Z, et al.
J Natl Cancer Inst
. 2019 Mar;
111(8):867-871.
PMID: 30888406
We retrospectively assessed association of stromal tumor-infiltrating lymphocytes (sTILs) with clinical outcomes and molecular variables reportedly predictive of trastuzumab-benefit in National Surgical Adjuvant Breast and Bowel Project B-31 (N = ...
3.
Mamounas E, Bandos H, Lembersky B, Jeong J, Geyer Jr C, Rastogi P, et al.
Lancet Oncol
. 2018 Dec;
20(1):88-99.
PMID: 30509771
Background: The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole...
4.
Geyer Jr C, Tang G, Mamounas E, Rastogi P, Paik S, Shak S, et al.
NPJ Breast Cancer
. 2018 Nov;
4:37.
PMID: 30456299
The NSABP B-20 prospective-retrospective study of the 21-gene Oncotype DX Breast Cancer Recurrence Score® test predicted benefit from addition of chemotherapy to tamoxifen in node-negative, estrogen-receptor positive breast cancer when...
5.
Mamounas E, Tang G, Paik S, Baehner F, Liu Q, Jeong J, et al.
Breast Cancer Res Treat
. 2017 Nov;
168(1):69-77.
PMID: 29128898
Background: The 21-gene recurrence score (RS) predicts outcome and benefit from adjuvant chemotherapy benefit in breast cancer patients treated with adjuvant endocrine therapy. In the NSABP B-28 study, we evaluated...
6.
Holmberg C, Bandos H, Fagerlin A, Bevers T, Battaglia T, Wickerham D, et al.
Cancer Prev Res (Phila)
. 2017 Oct;
10(11):625-634.
PMID: 28978566
Selective estrogen receptor modulators (SERMs) reduce breast cancer risk. Adoption of SERMs as prevention medication remains low. This is the first study to quantify social, cultural, and psychologic factors driving...
7.
Liu D, Ho M, Schaid D, Scherer S, Kalari K, Liu M, et al.
NPJ Breast Cancer
. 2017 Sep;
3:30.
PMID: 28856246
Our previous GWAS using samples from the NSABP P-1 and P-2 selective estrogen receptor modulator (SERM) breast cancer prevention trials identified SNPs in and near that were associated with breast...
8.
Qin S, Ingle J, Liu M, Yu J, Wickerham D, Kubo M, et al.
Breast Cancer Res
. 2017 Aug;
19(1):95.
PMID: 28821270
Background: We previously performed a case-control genome-wide association study in women treated with selective estrogen receptor modulators (SERMs) for breast cancer prevention and identified single nucleotide polymorphisms (SNPs) in ZNF423...
9.
Rastogi P, Wickerham D, Geyer Jr C, Mamounas E, Julian T, Wolmark N
Chin Clin Oncol
. 2017 Mar;
6(1):7.
PMID: 28285537
The National Surgical Adjuvant Breast and Bowel Project (NSABP) has made significant contributions in reducing the extent of breast surgery and in improving outcomes of patients with early-stage breast cancer...
10.
Mamounas E, Liu Q, Paik S, Baehner F, Tang G, Jeong J, et al.
J Natl Cancer Inst
. 2017 Jan;
109(4).
PMID: 28122895
Background: The 21-gene recurrence score (RS) predicts risk of locoregional recurrence (LRR) in node-negative, estrogen receptor (ER)-positive breast cancer. We evaluated the association between RS and LRR in node-positive, ER-positive...